Results of Phase 2 HD prevention and biomarker study (PRECREST) using high-dose of creatine published

A clinical study out of Massachusetts General Hospital that assessed the safety and tolerability of high doses of creatine was published online Friday in the journal of Neurology.  The study, also known as PRECREST, was the first secondary prevention trial in pre-manifest HD.  The goal of a secondary prevention trial is to treat existent disease in early stages before it can cause significant morbidity.  The study design allowed at-risk participants to enroll in the trial without having to learn if they carried the genetic mutation that causes HD. 

Creatine appeared to be both safe and tolerable to the small group of 32 study participants.  In addition, the rate of cortical (brain) thinning was significantly slower in the pre-manifest HD group that received creatine compared to the pre-manifest HD group that received a placebo.  The safety and imaging data suggest that larger clinical studies of creatine are warranted.

For more information on the PRECREST study please see the MGH press release Click here for release

A Phase 3 study assessing the efficacy of creatine in patients with early clinical features of HD (CREST-E) is currently enrolling.  For more information on this trial testing please see http://www.hdsa.org/research/clinical-trials-1/crest-e.html